Cargando…
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies hav...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130671/ https://www.ncbi.nlm.nih.gov/pubmed/34017337 http://dx.doi.org/10.3389/fimmu.2021.661135 |
_version_ | 1783694568234942464 |
---|---|
author | Satapornpong, Patompong Pratoomwun, Jirawat Rerknimitr, Pawinee Klaewsongkram, Jettanong Nakkam, Nontaya Rungrotmongkol, Thanyada Konyoung, Parinya Saksit, Niwat Mahakkanukrauh, Ajanee Amornpinyo, Warayuwadee Khunarkornsiri, Usanee Tempark, Therdpong Wantavornprasert, Kittipong Jinda, Pimonpan Koomdee, Napatrupron Jantararoungtong, Thawinee Rerkpattanapipat, Ticha Wang, Chuang-Wei Naisbitt, Dean Tassaneeyakul, Wichittra Ariyachaipanich, Manasalak Roonghiranwat, Thapana Pirmohamed, Munir Chung, Wen-Hung Sukasem, Chonlaphat |
author_facet | Satapornpong, Patompong Pratoomwun, Jirawat Rerknimitr, Pawinee Klaewsongkram, Jettanong Nakkam, Nontaya Rungrotmongkol, Thanyada Konyoung, Parinya Saksit, Niwat Mahakkanukrauh, Ajanee Amornpinyo, Warayuwadee Khunarkornsiri, Usanee Tempark, Therdpong Wantavornprasert, Kittipong Jinda, Pimonpan Koomdee, Napatrupron Jantararoungtong, Thawinee Rerkpattanapipat, Ticha Wang, Chuang-Wei Naisbitt, Dean Tassaneeyakul, Wichittra Ariyachaipanich, Manasalak Roonghiranwat, Thapana Pirmohamed, Munir Chung, Wen-Hung Sukasem, Chonlaphat |
author_sort | Satapornpong, Patompong |
collection | PubMed |
description | HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10(−7)), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10(−3)), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10(−5)) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10(−7)) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10(−3)). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population. |
format | Online Article Text |
id | pubmed-8130671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81306712021-05-19 HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients Satapornpong, Patompong Pratoomwun, Jirawat Rerknimitr, Pawinee Klaewsongkram, Jettanong Nakkam, Nontaya Rungrotmongkol, Thanyada Konyoung, Parinya Saksit, Niwat Mahakkanukrauh, Ajanee Amornpinyo, Warayuwadee Khunarkornsiri, Usanee Tempark, Therdpong Wantavornprasert, Kittipong Jinda, Pimonpan Koomdee, Napatrupron Jantararoungtong, Thawinee Rerkpattanapipat, Ticha Wang, Chuang-Wei Naisbitt, Dean Tassaneeyakul, Wichittra Ariyachaipanich, Manasalak Roonghiranwat, Thapana Pirmohamed, Munir Chung, Wen-Hung Sukasem, Chonlaphat Front Immunol Immunology HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10(−7)), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10(−3)), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10(−5)) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10(−7)) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10(−3)). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population. Frontiers Media S.A. 2021-05-04 /pmc/articles/PMC8130671/ /pubmed/34017337 http://dx.doi.org/10.3389/fimmu.2021.661135 Text en Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Satapornpong, Patompong Pratoomwun, Jirawat Rerknimitr, Pawinee Klaewsongkram, Jettanong Nakkam, Nontaya Rungrotmongkol, Thanyada Konyoung, Parinya Saksit, Niwat Mahakkanukrauh, Ajanee Amornpinyo, Warayuwadee Khunarkornsiri, Usanee Tempark, Therdpong Wantavornprasert, Kittipong Jinda, Pimonpan Koomdee, Napatrupron Jantararoungtong, Thawinee Rerkpattanapipat, Ticha Wang, Chuang-Wei Naisbitt, Dean Tassaneeyakul, Wichittra Ariyachaipanich, Manasalak Roonghiranwat, Thapana Pirmohamed, Munir Chung, Wen-Hung Sukasem, Chonlaphat HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients |
title |
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients |
title_full |
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients |
title_fullStr |
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients |
title_full_unstemmed |
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients |
title_short |
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients |
title_sort | hla-b*13 :01 is a predictive marker of dapsone-induced severe cutaneous adverse reactions in thai patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130671/ https://www.ncbi.nlm.nih.gov/pubmed/34017337 http://dx.doi.org/10.3389/fimmu.2021.661135 |
work_keys_str_mv | AT satapornpongpatompong hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT pratoomwunjirawat hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT rerknimitrpawinee hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT klaewsongkramjettanong hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT nakkamnontaya hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT rungrotmongkolthanyada hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT konyoungparinya hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT saksitniwat hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT mahakkanukrauhajanee hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT amornpinyowarayuwadee hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT khunarkornsiriusanee hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT temparktherdpong hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT wantavornprasertkittipong hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT jindapimonpan hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT koomdeenapatrupron hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT jantararoungtongthawinee hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT rerkpattanapipatticha hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT wangchuangwei hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT naisbittdean hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT tassaneeyakulwichittra hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT ariyachaipanichmanasalak hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT roonghiranwatthapana hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT pirmohamedmunir hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT chungwenhung hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients AT sukasemchonlaphat hlab1301isapredictivemarkerofdapsoneinducedseverecutaneousadversereactionsinthaipatients |